Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Revumenib Citrate

Placeholder slot
 (reh-VOO-meh-nib SIH-trayt)

Revumenib citrate works by binding to a protein called menin. This prevents menin from interacting with a rearranged form of the KMT2A protein made by an abnormal KMT2A gene found in some leukemia cells. Blocking the interaction between menin and the rearranged KMT2A protein helps slow or stop the growth of leukemia cells. Revumenib citrate is a type of targeted therapy called a menin inhibitor.

US Brand Name(s)
Revuforj
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Revumenib citrate is approved to treat adults and children aged 1 year and older with:

  • acute leukemia that has an abnormal KMT2A gene and has come back or did not respond to previous treatment

Revumenib citrate is also being studied in the treatment of other types of cancer.

More About Revumenib Citrate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Revumenib Citrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email